FDA对透黏膜速释芬太尼产品风险评估与缓解策略的评估
该研究对通过《信息自由法》获得的4877页FDA文件进行定性分析,包括2012—2017年6份年度REMS评估报告、FDA对报告的评估及FDA与申办方关于安全问题的通信。结果显示,项目启动12个月后,302名药师中24人(7.9%)、302名处方者中35人(11.6%)、192名患者中5人(2.6%)错误报告TIRF可用于阿片不耐受患者,后续报告维持类似误解水平。60个月时产品特异性索赔数据分析显示,34.6%至55.4%的TIRF处方患者为阿片不耐受。48个月调查中310名处方者中106人(34.2%)报告为慢性非癌痛阿片耐受患者开具TIRF;60个月时302名处方者中54人(18.4%)和310名患者中148人(47.7%)错误报告TIRF获FDA批准用于该用途。60个月期间REMS鲜有实质性修改以应对高比例超说明书使用证据,且虽有不依从计划但无处方者因不当处方被除名报告。
要点
- 项目启动12个月后,302名药师中24人(7.9%)、302名处方者中35人(11.6%)、192名患者中5人(2.6%)错误认为TIRF可用于阿片不耐受患者,后续报告误解水平相似。
- 60个月时产品特异性索赔分析显示,34.6%至55.4%的TIRF处方患者为阿片不耐受。
- 48个月调查中310名处方者中106人(34.2%)报告为慢性非癌痛阿片耐受患者开具TIRF。
- 60个月时302名处方者中54人(18.4%)和310名患者中148人(47.7%)错误报告TIRF获FDA批准用于慢性非癌痛。
- 60个月期间REMS鲜有实质性修改以应对高比例超说明书使用证据,且无处方者因不当处方被除名报告。
适用人群与场景
- 阿片耐受的突破性癌痛患者(TIRF适应症人群)。
- 药师、处方者和患者(REMS知识评估对象)。
研究设计与关键结果
- 研究类型:对4877页FDA文件的定性分析,包括2012—2017年6份年度REMS评估报告、FDA评估及FDA-申办方通信。
- 12个月时,302名药师中24人(7.9%)、302名处方者中35人(11.6%)、192名患者中5人(2.6%)错误报告TIRF可用于阿片不耐受患者,后续报告维持类似误解水平。
- 60个月时产品特异性索赔分析显示,34.6%至55.4%的TIRF处方患者为阿片不耐受。
- 48个月调查中310名处方者中106人(34.2%)报告为慢性非癌痛阿片耐受患者开具TIRF;60个月时302名处方者中54人(18.4%)和310名患者中148人(47.7%)错误报告TIRF获FDA批准用于该用途。
- 60个月期间REMS鲜有实质性修改以应对高比例超说明书使用证据,且无处方者因不当处方被除名报告。
证据类型、等级与局限
- 证据类型:定性分析(FDA文件审查)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Transmucosal immediate-release fentanyls (TIRFs), indicated solely for breakthrough cancer pain in opioid-tolerant patients, are subject to a US Food and Drug Administration (FDA) Risk Evaluation and Mitigation Strategy (REMS) to prevent them from being prescribed inappropriately.
OBJECTIVES: To evaluate knowledge assessments of pharmacists, prescribers, and patients regarding appropriate TIRF use; to describe sponsor assessments, based on claims data, of whether the REMS program was meeting its goals; and to characterize how the FDA responded to REMS assessments.
DESIGN, SETTING, AND PARTICIPANTS: Qualitative analysis of 4877 pages of FDA documents obtained through a Freedom of Information Act request, including 6 annual REMS assessment reports (2012-2017), FDA evaluations of these reports, and FDA-sponsor correspondence about safety issues.
EXPOSURE: A REMS program to reduce the risk of adverse outcomes, including misuse, abuse, addiction, and overdose, arising from use of TIRFs.
MAIN OUTCOMES AND MEASURES: (1) Knowledge assessments of pharmacists, prescribers, and patients; (2) survey and claims-based prescribing assessments; (3) FDA and TIRF sponsor communications; (4) modifications to the REMS program; and (5) disenrollment of noncompliant prescribers.
RESULTS: Twelve months after initiation of the program, 24 of 302 pharmacists (7.9%), 35 of 302 prescribers (11.6%), and 5 of 192 patients (2.6%) incorrectly reported that TIRFs can be prescribed to opioid-nontolerant patients, with similar levels of misunderstanding maintained in the subsequent reports. At 60 months, product-specific analyses of claims data indicated that between 34.6% and 55.4% of patients prescribed TIRFs were opioid-nontolerant. In the 48-month survey, 106 of 310 prescribers (34.2%) reported prescribing TIRFs for opioid-tolerant patients with chronic, noncancer pain; at 60 months, 54 of 302 prescribers (18.4%) and 148 of 310 patients (47.7%) erroneously reported that TIRFs were FDA-approved for such use. Over the 60-month period examined, there were few substantive changes made to the REMS to address evidence of high rates of off-label TIRF use, and, although the REMS program had a noncompliance plan, there was no report of prescribers being disenrolled for inappropriate prescribing.
CONCLUSIONS AND RELEVANCE: In this review of FDA documents pertaining to the TIRF REMS, surveys of pharmacists, prescribers, and patients reflected generally high levels of knowledge regarding proper TIRF prescribing, yet some survey items as well as claims-based analyses indicated substantial rates of inappropriate TIRF use. Despite these findings, the FDA did not require substantive changes to the program.
参考来源
- Rollman JE, Heyward J, Olson L, et al. Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl Products. JAMA. 2019. PMID: 30778596. doi:10.1001/jama.2019.0235
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。